Dunya Mohammad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dunya Mohammad has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Rossana Baracco
Division of Pediatric Nephrology and Hypertension Department of Pediatrics Children's Hospital of Michigan Central Michigan University Detroit Michigan USA
3 shared publicationsMelissa Gregory
Division of Pediatric Nephrology, Children’s Hospital of Michigan, Detroit, USA
2 shared publicationsShannon Leikert
Division of Pediatric Nephrology, Children’s Hospital of Michigan, Detroit, USA
2 shared publicationsAhmad Farooqi
Clinical Research Institute, Central Michigan University College of Medicine, Detroit, MI
1 shared publication- Amrish Jain
Division of Pediatric Nephrology and Hypertension Department of Pediatrics Children's Hospital of Michigan Central Michigan University Detroit Michigan USA
1 shared publication - Arul Chandran
Division of Pulmonary Diseases and Critical Care, Hurley Medical Center, G-3252 Beecher Road, Flint, MI 48532, USA
1 shared publication
Latest Publications
- 1 March 2022
- Published by Elsevier in The Journal of Pediatrics
- Vol. 242, 201-205.e1
Kidney Echogenicity and Vesicoureteral Reflux in Children with Febrile Urinary Tract Infection
- 1 March 2022
- Published by Elsevier in The Journal of Pediatrics
- Vol. 242, 201-205.e1
Kidney Echogenicity and Vesicoureteral Reflux in Children with Febrile Urinary Tract Infection
- 5 February 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (4) , e14241
Treatment of BK virus with a stepwise immunosuppression reduction and intravenous immunoglobulin in pediatric kidney transplant
Background: BKV and BKVN are common in pediatric kidney transplant, but there is limited data on treatment approaches. Our objective was to study the prevalence of BKV and BKVN utilizing only plasma qPCR and report treatment outcomes with stepwise IR and IVIG.Methods: A retrospective study of all pediatric kidney transplants from 2013 to 2020. Excluded patients >21 years at transplant and immediate graft failure. Surveillance was conducted using only plasma BK qPCR at 1, 3, 6, 9, 12, 18, and 24 months and annually. BKV defined as ≥250 copies/ml and resolution as 10 000 copies/ml despite IR; and BKVN if confirmed on histology.Results: Fifty‐six patients were included in the study; 20 (35.7%) had BKV. BKV was associated with longer duration of stent, 40 vs. 33.5 days (p = .004). Two patients (3.5%) had confirmed, and 2(3.5%) had presumed BKVN. The first‐line treatment was IR in 100% of patients. BKVN confirmed and presumed received IVIG every month for six doses. Viral resolution was achieved in 70%, and no difference was noted in estimated glomerular filtration rate between BKV and non‐BKV group (p = .438). There were no rejection episodes, and graft survival was 100% over median follow‐up of 3 years.Conclusions: Plasma qPCR alone is adequate for screening and monitoring treatment of BKV and BKVN. A stepwise IR and IVIG resulted in BKV resolution in the majority of patients. Larger studies are required to study the role of IVIG in the treatment of BKVN.
- 5 February 2022
- Published by Wiley in Pediatric Transplantation
- Vol. 26 (4) , e14241
Treatment of BK virus with a stepwise immunosuppression reduction and intravenous immunoglobulin in pediatric kidney transplant
Background: BKV and BKVN are common in pediatric kidney transplant, but there is limited data on treatment approaches. Our objective was to study the prevalence of BKV and BKVN utilizing only plasma qPCR and report treatment outcomes with stepwise IR and IVIG.Methods: A retrospective study of all pediatric kidney transplants from 2013 to 2020. Excluded patients >21 years at transplant and immediate graft failure. Surveillance was conducted using only plasma BK qPCR at 1, 3, 6, 9, 12, 18, and 24 months and annually. BKV defined as ≥250 copies/ml and resolution as 10 000 copies/ml despite IR; and BKVN if confirmed on histology.Results: Fifty‐six patients were included in the study; 20 (35.7%) had BKV. BKV was associated with longer duration of stent, 40 vs. 33.5 days (p = .004). Two patients (3.5%) had confirmed, and 2(3.5%) had presumed BKVN. The first‐line treatment was IR in 100% of patients. BKVN confirmed and presumed received IVIG every month for six doses. Viral resolution was achieved in 70%, and no difference was noted in estimated glomerular filtration rate between BKV and non‐BKV group (p = .438). There were no rejection episodes, and graft survival was 100% over median follow‐up of 3 years.Conclusions: Plasma qPCR alone is adequate for screening and monitoring treatment of BKV and BKVN. A stepwise IR and IVIG resulted in BKV resolution in the majority of patients. Larger studies are required to study the role of IVIG in the treatment of BKVN.
- 1 March 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 36 (3) , 577-580
A 6-year-old male with acute kidney injury and enlarged kidneys: Answers
- 1 March 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 36 (3) , 577-580
A 6-year-old male with acute kidney injury and enlarged kidneys: Answers
- 10 July 2020
- Published by Springer Nature in Pediatric Nephrology
- Vol. 36 (3) , 575-576
A 6-year-old male with acute kidney injury and enlarged kidneys: Questions
- 10 July 2020
- Published by Springer Nature in Pediatric Nephrology
- Vol. 36 (3) , 575-576
A 6-year-old male with acute kidney injury and enlarged kidneys: Questions
- 1 August 2019
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 144 (2_MeetingA) , 392
Sonographic Inferior Vena Cava Assessment to Predict Fluid Responsiveness in Patients with Sepsis
- 1 August 2019
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 144 (2_MeetingA) , 392
Sonographic Inferior Vena Cava Assessment to Predict Fluid Responsiveness in Patients with Sepsis